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i 
Abstract 
The ability to trigger the degradation of polymeric nanoparticles (NPs) by a specific 
stimulus can provide a method of improved drug targeting and selective 
release capabilities in vivo. The challenge for most polymeric drug delivery systems 
remains the necessity for many stimuli events to trigger the release of cargo. Polymeric 
nanotechnology containing “self-immolative polymers” looks to alleviate the reliance 
on high concentrations of stimuli by undergoing complete end-to-end depolymerization 
via a single stimulus-mediated reaction of an end-cap. Herein, NPs were developed using 
poly(ethyl glyoxylate) (PEtG) blended with poly(D,L-lactic acid) (PLA) to encapsulate a 
hydrophobic cargo to be released upon stimulus-triggered cleavage of the PEtG end-
cap. The PEtG-PLA NPs were formed using an oil-in-water emulsion-evaporation 
technique. Particles responsive to stimuli including UV-light and reducing 
conditions were prepared and studied. Cleavage of the end-caps of these polymers was 
accomplished by introducing the relevant stimuli, resulting in a rapid degradation of the 
particles and subsequent release of cargo. Nile red as a fluorescent probe and the 
drug celecoxib were encapsulated within the particles and were shown to be released 
upon introduction of small amounts of the appropriate stimulus. Initial cell culture studies 
were performed to investigate the behavior of the systems in vitro. This system provides 
the ability to tune the responsiveness of the NPs by simply changing the PEtG end-
cap, making them a great prospect for stimuli-responsive drug delivery vehicles. 
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1 
1 Introduction 
Polymers are a versatile class of materials which can be produced on industrial scales and 
their properties can be easily tuned for a wide array of applications. The synthesis and 
manufacturing of polymeric materials increased as the realization of their versatility in a 
broad range of products became apparent. These ubiquitous materials emerged in the 
early 1900’s and found applications in many industries including rubber, plastic, 
petrochemical, packaging, agriculture, and pharmaceuticals (Figure 1).  
 
Figure 1. Historical breakthroughs in the field of polymeric materials. 
With the discovery of polystyrene and polypropylene, the world began producing 
hundreds of tons of plastic every year.1, 2  Synthetic rubbers were already in production 
by the 50’s with production of just under one million tons per year. By 2016, over 300 
million tons of plastic and 26 million tons of rubber were produced worldwide.3 
Synthetic polymers have led to a plethora of versatile materials and inventions that have 
shaped today’s society. The inherent properties of polymers make them adaptable 
materials. As one small change is made to a monomer, this change can be propagated 
through the polymer chain resulting in an overall polymer with starkly different physical 
and chemical properties. Because of their sensitivity to minute changes in their monomer 
structures, polymers have highly tunable physical and chemical properties that can be 
readily manipulated either chemically by altering the monomer structure, or by blending 
with plasticizers and other polymers. The versatility of polymers allows scientists to 
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create polymeric systems and materials with a wide array of applications from everyday 
commercial products to highly advanced drug delivery systems (DDS).4     
There exist many benefits to polymers; however, there remains the problem of how to 
dispose of these materials once used. The majority of waste generated from plastics and 
petrochemicals is non-compostable and nondegradable and accounts for over 10% of 
total municipal waste.5 Incineration of these materials can release pollutants into the 
atmosphere and recycling methods have proved to be costly and relatively inefficient. 
The high stability, low solubility, potential toxicity and sheer volume make these 
polymers difficult and expensive to dispose of efficiently.6 To address these critical 
issues, degradable polymers that can exhibit the desirable properties of traditional 
nondegradable polymers have emerged.2   
1.1 Degradable Polymers 
As attention has shifted towards decreasing waste buildup and toxic degradation products 
of synthetic polymers, the focus has turned to the development of non-toxic, degradable 
polymers without sacrificing too many of the desirable characteristics of traditional 
plastics such as structural strength or durability.7 Synthetic polymers can be divided into 
two major categories based on the chemical composition of their backbone: polymers 
with heteroatom-containing backbones and polymers with only carbon-containing 
backbones.8 Polymers with only carbon-containing backbones consist of carbon-carbon 
bonds throughout the backbone of the macromolecule while polymers with heteroatom-
containing backbones offer the advantage of having atoms other than carbon in the main 
chain backbone. Heteroatoms commonly used in these polymers include phosphorous 
(polyphosphoesters, e.g., 1.1), nitrogen (polycaprolactam, e.g., 1.2), and oxygen 
(poly(ethylene glycol), e.g., 1.3) (Figure 2). 
 
1.1 
 
1.2 
 
1.3 
Figure 2. Examples of polymers with heteroatom-containing backbones. 
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While carbon-carbon bonded polymers yield very stable and relatively inert backbones, 
heteroatoms introduce polarity into the polymer backbone which can be exploited for 
chemical cleavage reactions.9 Traditional rubbers and plastics are composed of carbon-
chain polymers i.e. polybutadiene (1.4), polystyrene (1.5), polypropylene (1.6), and 
poly(vinyl chloride) (PVC, 1.7) as shown in Figure 3. 
 
1.4 
 
1.5 
 
1.6 
 
1.7 
Figure 3. Examples of polymers with only carbon in their backbone. 
The polymers in Figure 3 are very durable and inert materials. The introduction of 
heteroatoms, however, introduces potential areas to exploit for cleavage of the backbone 
leading to erosion and degradation of the material. For example, inserting oxygen atoms 
throughout the polymer backbone leads to a polyether. While the ether functional group 
is quite stable and exhibits low chemical reactivity, their polar bonds can be cleaved by 
the introduction of strong acids.10   
1.1.1 Polyesters    
Over the past three decades, research has yielded a vast library of degradable materials 
with wide-scope applications into many fields including pharmaceutics, agriculture, 
tissue engineering and commodities.11, 12 Current degradable polymers include polyesters, 
polyacetals, polyamides, polyanhydrides, polyphosphazenes, polysulphones, 
polysiloxanes, polyurethanes and polydisulfides. In each of these cases, a heteroatom 
exists in the polymer backbone which leaves the polymer susceptible to cleavage 
reactions. Of all the different functional groups of degradable polymers, polyesters have 
been the most studied because they can be tailored to exhibit desirable properties 
including biocompatibility and biodegradability.8 These properties will be discussed in 
more detail below. 
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In the early 1950’s reports of the first synthetic degradable polyesters, such as 
polydioxanone (1.8), poly-3-hydroxyalkanoate (1.9), polyvalerolactone (1.10), and 
polycaprolactone (PCL, 1.11) were reported for applications in the plastic industry 
(Figure 4).4 The hydrolysable ester groups throughout these polymer backbones increase 
the polymer’s susceptibility to degradation, significantly increasing their degradation 
rates. The problem continues to be that these materials are not as cost effective for large 
scale production as the more commonly used polymers such as high-density 
polyethylene, low density polyethylene and polypropylene. 
 
Figure 4. Common degradable polyesters. 
An important feature of degradable polymers to consider is their biocompatibility. There 
exists a subset of degradable polymers that are not only degradable, but also display 
biodegradability - a feature defined as polymers that can be cleaved and degraded using 
biological machinery. Biodegradable polymers have backbone linkages that can be 
cleaved either by hydrolysis and/or enzyme-mediated within an organism.13 The majority 
of biodegradable polymers currently in use are polyesters, including PCLs, poly(glycolic 
acid) (PGA, 1.12), poly(D,L-lactic acid) (PLA, 1.13) and poly(L-lactic acid). Variations of 
these homopolymers along with a variety of blends and copolymers (1.14) of these 
polyesters have been synthesized and proven to afford biodegradability. Figure 5 shows 
the most common polyesters used in medical applications. Applications of these 
polymers have been reported in medical devices, tissue engineering scaffolds, and drug 
delivery vehicles.14-16 
 
Figure 5. The most common biodegradable polyesters for medical applications. 
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While many of these materials have proved to be of great benefit, there still exist some 
limitations inherent to the degradation process of common degradable polymers. 
Degradable polymers rely on many chain scission cleavage events to slowly break down 
the long polymer chains into shorter fragments. Over time, this process leads to a 
complete degradation of the polymer. The degradation time of the polymer can be tuned 
by manipulating the properties of the polymer either chemically or by mixing one 
polymer with another to form a blend. However, the degradation of these polymers still 
includes some inherent randomness or uncontrollable processes.17 Polyesters degrade by 
many hydrolysis events of the ester linkages throughout the backbone. The overall rate 
may be tuned to some degree, but the user has no control over where and when 
hydrolysis occurs throughout the backbone. The process of degradation is simply random 
in nature leaving little control as to specific ester bond cleavages. While polyesters and 
other biodegradable polymers have made a big impact in healthcare and pharmaceutics, 
there remain some limitations to these polymeric systems that could potentially be 
improved upon. 
In recent years, the evolution of degradable polymers has lead research towards polymers 
that are not just degradable, but degradable upon introduction of a specific stimulus. The 
question of how to gain control over the degradation process was addressed with the 
emergence of self-immolative polymers (SIPs).18 
1.2 The Development of Self-Immolative Polymers 
1.2.1 Stimuli-Responsive Polymers 
To overcome the lack of control in degradation of common degradable polymeric 
materials, attention has moved to the development of stimuli-responsive polymers. 
Stimuli-responsive polymers exhibit triggerable degradability upon exposure to a specific 
stimulus. These polymers are synthesized with functional groups that have an inherent 
sensitivity to certain conditions such as reduction/oxidation chemistry or acid/base 
chemistry. These polymers show responsiveness when exposed to a specific stimulus that 
will ultimately lead to their degradation. Specific polymers developed for this purpose 
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include polyacetals, polydisulfides (1.15), poly(ortho esters) (1.16), polyketals (1.17) and 
others. (Figure 6).19 
 
1.15 
 
1.16 
 
1.17 
Figure 6. Common stimuli-responsive polymers. 
Stimuli-responsive polymers can give rise to materials that exhibit sensitivity to pH 
(1.17), reduction (1.15) and temperature (1.16). Other stimuli-responsive polymers exist 
that show responsive behavior to a variety of other factors including humidity, 
wavelength or intensity of light, and magnetic fields. The physical response from these 
polymers can be a variety of changes such as altering solubility, color, transparency, 
conductivity or shape.20, 21 However, not all of these classes of stimuli-responsive 
polymers are useful in applications where degradable polymers are required.      
The introduction of stimuli-responsive polymers gives the user a more “degrade-on-
demand” property to these polymers, but similar to the limitation of polyesters, stimuli-
responsive polymers require many stimulus events to completely degrade the backbone. 
Therefore, these polymers can only be used in situations where stimulus is plentiful. It 
wasn’t until the emergence of “self-immolative” molecules that scientists could begin to 
control specific stimulus-bond cleavage interactions. 
1.2.2 Self-Immolative Small Molecules   
A self-immolative system contains a stable bond between protecting and leaving groups 
(LGs) which becomes labile upon activation leading to a “triggerable” release of the 
LG.22 In 1981, Katzenellenbogen and coworkers introduced the first self-immolative 
spacer into a prodrug delivery system.23  The spacer was based on p-aminobenzyl 
alcohol, which could undergo a 1,6 elimination reaction to release a LG. This reaction 
was protected with a triggerable protecting group (PG) on the amine and the drug was 
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attached through a carbonate bond to the alcohol. With proper stimulus, the aromatic 
amine can be exposed to undergo the elimination step, releasing the drug (Scheme 1).  
 
Scheme 1. 1,6-elimination mechanism of p-aminobenzyl ester (Nu = nucleophile). 
The purpose of introducing a spacer between the concealed drug and the PG was to 
increase the distance between the bulky drug and the PG. Having the bulky drug close to 
the PG was shown to reduce the enzymatic cleavage rate of some prodrugs. 
Katzenellenbogen showed by introducing a self-immolative linker between the two 
molecules lead to increased enzymatic cleavage due to reduced steric hindrance. Many 
variations of this 1,6-elimination linker have been developed by using aromatic amine, 
hydroxyl or thiol moieties, each undergoing a 1,6-elimination reaction.24   
While the use of prodrugs has led to promising applications in therapeutics, the inherent 
limiting factor to these types of systems is the continual need of stimulus to release drug. 
For each equivalent of drug released, there needs to be an equal equivalent of stimulus 
events. This limits the scope of potential PG that could be used for triggered removal of 
prodrugs. In certain situations, where specific stimuli concentrations are low, it would be 
beneficial to have a system in which one triggering event could lead to many equivalents 
of drug to be released. The combined work of these early reports of self-immolative 
molecules laid the groundwork for more promising macromolecular structures. 
1.2.3 Self-Immolative Macromolecules   
The invention of self-immolative linkers led to an expansive idea of combining several of 
these linkers successively to create macromolecular structures.25 Self-immolative 
oligomers and dendrimers were introduced in the early 2000’s. These macromolecular 
structures were developed in an attempt to amplify responsiveness of self-immolative 
linkers to stimuli. Self-immolative oligomers consist of several linkers covalently bonded 
together, typically as dimers or trimers. Self-immolative dendrimers are composed of 
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repeated branches that are organized in concentric layers called “generations” around a 
central core or focal point.26 Both have been investigated for applications in drug 
delivery.   
In 2001, Scheeren and coworkers published the first self-immolative oligomer consisting 
of derivatives of naphthyl and biphenyl moieties that underwent a cascade elimination 
mechanism similar to that of the earlier aminobenzyl alcohols (Scheme 2a).27 These 
linkers, along with p-aminobenzyl alcohol linker, can be successively bonded together by 
carbamate bonds into oligomers. The terminal amine can be deprotected, resulting in 
successive 1,10-elimination decarboxylation reactions to release a LG (Scheme 2b). 
 
Scheme 2. (a) 1,8-elimination mechanism of a naphthyl-based linker and (b) 1,10-elimination 
mechanism of a biphenyl-based linker. 
Unfortunately, it was shown that the naphthyl and biphenyl systems failed to undergo the 
hypothesized elimination cascades. It was hypothesized the energetic cost in 
dearomatizing the systems in the 1,8- and 1,10-eliminations were too high to achieve a 
rapid reaction. The aminobenzyl alcohol oligomer, however, could successfully undergo 
consecutive elimination decarboxylation mechanisms to release a payload. The ratio to 
stimulus events to molecules of cargo released in these systems is still 1:1, but it laid the 
ground work for future linear and dendritic systems for signal amplification.  
In 2008, Kratz developed the first self-immolative oligomer system that showed 
increased drug release rates by amplification of stimulus.28 Kratz’s oligomer was based 
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on a similar 1,6-elimination mechanism as above, but the model drug was also 
conjugated to the aromatic moieties such that they could be released via 1,4-elimination 
reactions. The stimulus could be amplified in this system due to multiple molecules of 
model drug being released for one deprotection reaction (Scheme 3). Three equivalents of 
a carbamate-linked cargo moiety could be released upon a single stimulus event. 
 
 
Scheme 3. A self-immolative oligomer capable of 1,6-eliminations through its backbone and 
1,4-eliminations of pendant groups. 
As the development of self-immolative oligomers continued, another class of self-
immolative macromolecular structures were being investigated. In 2003, the first self-
immolative dendrimeric system was reported by McGrath and coworkers.26 A dendrimer 
consists of repeated branches organized into layers all stemming from a common focal 
point. McGrath’s group used a 2,4-bis(hydroxymethyl)phenol monomer with each 
generation linked in succession (Scheme 4). Through cleavage of an allyloxybenzyl ether 
group at the focal point, the cascade elimination that followed released four nitrophenol 
molecules. 
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Scheme 4. Example of 2,4-bis(hydroxymethyl)phenol-based dendrimer. 
Once again, the self-immolative nature of this system relied on an elimination cascade 
that propagates through several conjoined fragments to eliminate a cargo molecule. The 
major advantage to dendrimeric systems is their amplification of the stimulus. With 
McGrath’s early dendrimer, one stimulus event at the focal point allyl ether led to the 
release of four equivalents of cargo molecule, p-nitrophenol. However, the difficulty 
surrounding dendrimers is their cumbersome synthesis procedures. In addition, the 
number of generations eventually reaches a maximum due to steric hindrance, leading to 
a limit in how much cargo can be conjugated and released. 
Dendrimeric structures continue to be investigated as drug delivery vehicles with 
promising properties.25, 26, 29 With the development of self-immolative oligomers and 
dendrimers in place, the next logical step was to investigate SIPs as potential stimuli-
responsive materials.   
1.2.4 Self-Immolative Polymers  
SIPs are able to amplify a polymer’s sensitivity to a stimulus by only requiring a single 
stimulus event to initiate a spontaneous chain depolymerization reaction.30 These 
polymers can be stabilized by protecting their ends with a stimuli-responsive small 
molecule. This is called “end-capping”. Once a SIP has been properly end-capped, it can 
then be handled under ambient conditions without significant degradation (Figure 7). 
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However, cleavage of the end-cap results in end-to-end depolymerization by a cascade of 
reactions. 
 
Figure 7. End-capped stabilized SIP subjected to end-cap cleavage followed by 
depolymerization. 
Small molecules used to end-cap polymers that show specific stimuli-responsive behavior 
are termed stimuli-responsive end-caps. End-caps have shown sensitivity to a range of 
stimuli including chemical, ultraviolet (UV) light, pH, temperature and redox potential.30, 
31 In each case, the stimulus triggers a specific chemical reaction at the end-cap leading to 
detachment from the polymer. The polymer, no longer protected, undergoes a rapid end-
to-end depolymerization. 
To date there are two subclasses of SIPs that are distinguished by the mechanism that 
governs their depolymerization. The first class of SIPs spontaneously degrade into 
products that are different from the monomers used to synthesize the polymer.32, 33 
Depolymerization is favored and happens spontaneously due to the stability of the 
degradation products. The second class of SIPs is governed by the polymer’s low ceiling 
temperature (Tc). Upon cleavage of these stimuli-responsive end-caps, entropy drives 
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depolymerization of the polymer back to monomer units.34 This phenomenon can be 
better understood by examining thermodynamics of polymerizations.   
From the Gibbs free energy equation, the free energy of a polymerization reaction is the 
sum of both the enthalpic and entropic contributions (eq. 1).   
ΔG = ΔH – TΔS      eq. 1 
ΔG = ΔH – TΔS = 0      eq. 2 
T = ΔH/ΔS = Tc      eq. 3 
For a given monomer with a set concentration, the enthalpy and entropy are fixed and 
specific to that monomer. Therefore, the only variable that can be manipulated is the 
temperature. An appropriate temperature must be found to make ΔG negative giving a 
spontaneous reaction of monomers into polymer. Furthermore, there must exist a 
temperature where ΔG = 0 (eq. 2) and the system is in equilibrium. In other words, the 
rate of polymerization is equivalent to the rate of depolymerization.  At ΔG = 0, 
temperature can be calculated by the ratio of ΔH and ΔS (eq. 3). This is called the 
polymer’s Tc. At temperatures above a polymer’s Tc, the rate of depolymerization is 
faster than the rate of polymerization. Conversely, at temperatures below the Tc of a 
polymer, the rate of polymerization is faster than the rate of depolymerization. This 
principle can also be represented graphically (Figure 8).35 
 
Figure 8. Rates of depolymerization and polymerization as a function of temperature. They 
intersect at the Tc. 
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The second class of SIPs takes advantage of polymers with lower than ambient Tc. The 
monomers are first polymerized below their Tc, allowing for the growth of long chains. 
Then, before the material is allowed to warm, the ends of the polymer chains are capped 
with a stimuli-responsive small molecule to trap the polymer chains and stabilize the 
system. The material can then be warmed to temperatures higher than the Tc and can be 
manipulated for different applications. When this material is subjected to its responsive 
stimulus at ambient temperatures, the stabilizing end-cap substituents are removed and 
the material spontaneously degrades.36 The major advantage to SIPs is their ability to 
amplify the response to a stimulus. One cleavage event at a polymer end-cap leads to 
complete end-to-end depolymerization of the entire polymer chain.  In 2008, Shabat 
reported the first SIP, which belongs to the first class of SIPs. The Shabat polmyer 
consisted of a polycarbamate backbone that upon removal of the 
bis(trimethylsilyl)acetamide-responsive end-cap, underwent a domino-like 1,6-
elimination-decarboxylation cascade, resulting in complete degradation of the 
macromolecule into carbon dioxide and azaquinone methide (Scheme 5).18 Altering the 
sensitivity of the end-caps to a variety of stimuli yielded a material that could be 
triggered to degrade in response to different triggers. The versatility of these materials 
has provided efficacy in a multitude of areas including drug delivery, bio-sensors, 
agriculture, and consumer products.37-40  
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Scheme 5. Degradation mechanism of a polycarbamate-based SIP. 
In 2009, Dewit and Gillies reported another carbamate-based SIP that degraded through 
alternating intramolecular cyclization and 1,6-elimination reactions (Scheme 6).41 The 
backbone consisted of alternating N,N’-dimethylethylenediamine and 4-hydroxybenzyl 
alcohol units linked through carbamate bonds. A tert-butylcarbamate (Boc) group was 
used to protect the terminal amine as a model end-cap. The polycarbamate was stable in 
aqueous solution, but upon removal of the Boc group from the amine, an intramolecular 
cyclization revealed the phenol to undergo a 1,6-elimination followed by a 
decarboxylation to yield a consecutive free amine. The cascade continued from end-to-
end until the polymer completely degraded into N,N’-dimethylimidazolidinone, CO2, and 
4-hydroxybenzyl alcohol products. The intramolecular cyclization step was the slower, 
rate determining step in the degradation mechanism. In follow-up work, the insertion of 
different cyclization reactions was used to tune the rate of depolymerization.42 
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Scheme 6. Cyclization depolymerization mechanism of a SIP. 
Phillips furthered the versatility of the SIP backbones by developing a polyacetal SIP 
based on phthalaldehyde (Scheme 7).43 This backbone belongs to the second class of 
SIPs, with degradation governed by the low Tc. By using a chloroformate derivative of 6-
nitroveratrole, a polyphthalaldehyde-based SIP that exhibited responsivity to UV light 
was produced.  His group later showed this polymer was capable of forming 
microparticles that could be triggered to release a cargo upon introduction of UV 
light.44,45 Due to the low Tc of polyphthalaldehyde (PPHA), polymerization of the 
dialdehyde was carried out at -78 °C. The end-cap reaction of terminal hemiacetal was 
conducted before the material was allowed to warm to room temperature. They also 
proved control over molecular weights by correlating the Mn to the concentration of the 
initiator. At ambient temperatures, just 30 minutes of UV radiation reduced the weight 
percent (wt%) of polymer coatings by 90%. 
 
Scheme 7. Degradation mechanism of polyphthalaldehyde. 
While the above backbones are promising and in further development, the degradation 
products of these SIPs are known to show toxicity in vitro. This has made the use of SIPs 
as potential drug delivery materials difficult. However, over the past several years, Gillies 
has developed another polyacetal SIP, poly(ethyl glyoxylate) (PEtG), that holds the 
potential to be non-toxic.46 Similar to PPHA, PEtG is a polyacetal SIP with a low Tc of 
around -5 °C. The polymerization is carried out at -40 °C to -20 °C in the presence of a 
16 
catalytic amount of triethylamine (TEA) (Scheme 8a). Our current hypothesis is that TEA 
acts as a proton shuttle during the polymerization. The polymerization is believed to 
initiate from trace amounts of hydrate present in the monomer solution. At room 
temperature, non-end-capped PEtG chains spontaneously depolymerize back to ethyl 
glyoxylate monomer units (Scheme 8b). 
 
Scheme 8. (a) Synthesis of PEtG and (b) Depolymerization mechanism for PEtG and 
subsequent hydration/hydrolysis of the corresponding small molecules. 
The hemiacetal ends can be capped by the addition of chloroformate derivatives of 
stimuli-responsive small molecules, creating carbonate linkages between the polymer and 
end-cap. The most promising feature of PEtG is that in vitro these monomers ultimately 
degrade into glyoxylic acid hydrate and ethanol, both of which should be relatively 
nontoxic and can be processed by the human body.47 It is hypothesized that drug delivery 
vehicles manufactured from PEtG could provide an SIP-based DDS in the form of 
polymeric self-assemblies. 
For PEtG to be a viable drug delivery material, the polymer needs to be stable in 
biological conditions of 37 °C. To achieve this, the hydroxyl end groups of the polymer 
are stabilized by reacting them with stabilizing small molecules. These molecules protect 
the reactive ends of the polymer and hinder end-to-end depolymerization, resulting in a 
polyacetal that is quite stable at physiological pH and temperature. A range of end-caps 
have been reported for this purpose.  The few that are important to this thesis are benzyl 
chloroformate (BnCF), which is non-responsive and serves as a control (1.18); 6-
nitroveratryl chloroformate (NVOC-Cl), which is sensitive to UV light (1.19); and 2-
(pyridine-2-yl-disulfanyl)ethyl chloroformate (PDS-Cl), which is sensitive to reducing 
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conditions (1.20) (Figure 9).48 These molecules react with hemiacetal alcohols at the 
termini of the polymer to yield BnCO-, NVOC-, and disulfide-capped PEtG polymers. It 
has been shown in previous work by Gillies and coworkers that these end-caps stabilize 
the PEtG polymers and allow them to withstand temperatures over 120 °C without 
degradation in the dry state. 
 
1.18 
 
1.19 
 
1.20 
Figure 9. Chloroformate-based molecules for end-capping PEtG. 
From the past decade of research into SIPs as potential candidates for stimuli-responsive 
DDSs, it is hypothesized that PEtG could be a promising material in this field due to its 
amplified response to stimuli and its potentially non-toxic degradation products. 
1.3 Polymeric Drug Delivery Systems 
One important potential application of SIPs is in polymeric DDSs. Polymer assemblies 
including micelles, worm-like micelles, vesicles, and solid-core particles have been 
extensively researched and developed for biomedical and drug delivery purposes. PLA, 
PGA, PCL, PEO and their copolymer assemblies have been extensively applied towards 
drug delivery research with varying degrees of success.49-52 From decades of polymeric 
self-assembly research, several important features for an efficient polymeric DDS have 
been determined. First, the polymer must exhibit an acceptable host response and its 
degradation products must be considered non-toxic.53 Second, there is a specific range of 
sizes for a DDS to ensure it does not get cleared from the body before it can deliver its 
payload.54 Third, the DDS must be capable of carrying significant loads of cargo and also 
releasing their cargo in the short time frame they remain in circulation.55 DDSs that do 
not meet at least these criteria, show inefficient treatment results in vivo.56 
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1.3.1 Self-Assembled Nanostructures 
Lipid-based vesicles were among the first nanotechnology DDSs.16 These structures 
consist of a self-assembled sphere of phospholipids that surround a water droplet. It is 
well understood that when phospholipids are placed in an aqueous environment, they 
spontaneously arrange themselves in order to minimize unfavorable hydrophobic-
hydrophilic interactions. This creates a bilayer where the hydrophobic tails of the 
phospholipids are close to one another and oriented away from the aqueous surroundings. 
This leaves the hydrophilic heads of the phospholipids arranged outward toward the 
aqueous surrounds. Ultimately, spherical structures are formed with the inside filled with 
the aqueous media (Figure 10a).   
 
Figure 10. (a) Self-assembled phospholipid liposome and (b) Self-assembled polymersome. 
Similar structures can be made using other biologically-based materials that possess 
amphiphilic properties including polypeptides (Figure 10b) and polysaccharides.57 These 
technologies have seen much clinical success due to their biocompatibility and low 
toxicity in vivo.     
Similar to amphiphilic phospholipids and polypeptides, polymers also exhibit self-
assembling behavior in solution. Polymers with amphiphilic properties orient themselves 
to minimize unfavorable interactions with the surrounding solvent. Amphiphilic polymers 
are typically made by sequential polymerization of hydrophobic block and hydrophilic 
blocks or by the conjugation of these blocks post-polymerization. Depending on the ratio 
of the blocks, different self-assembled structures can be made.58 With a higher fraction of 
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hydrophilic block, micelle structures are typically formed (Figure 11a). With a higher 
fraction of hydrophobic block, vesicle structures are often formed (Figure 11c). Marginal 
differences in the hydrophobic:hydrophilic ratio lead to intermediate structures like the 
worm-like micelle (Figure 11b). For hydrophobic homopolymers, solid-core particles 
form and can be suspended in aqueous solution by the addition of a surfactant to coat the 
surface of the particles (Figure 11d).   
 
Figure 11. Examples of self-assembled architectures based on polymers containing different 
ratios of hydrophobic and hydrophilic blocks. 
Biodegradable polymers can serve as alternatives to lipids. One benefit of using polymers 
is their degradability can be tuned to control when and/or how fast a drug is released. The 
common polyesters, PLA, PGA and their copolymers have been the most widely studied 
for drug delivery.8, 13, 50 Degradation rates can be tuned in the range of weeks to years 
using different compositions of these polymers. A major drawback is their relative 
instability in blood compared to liposomal counterparts. Intravenous injection being one 
of the most effective ways to treat disease, it is important to understand and develop 
DDSs capable of withstanding the blood stream.59 
1.3.2 Clearance of DDSs from the Body 
When a therapeutic drug delivery vehicle is administered into a person’s blood stream, a 
number of biological factors diminish or limit the overall efficacy of the DDS.53 
Depending on how the DDS are administered into the body, they must bypass a number 
of barriers in order to reach their therapeutic target. The body is effective at identifying 
foreign objects within and has a variety of effective ways it can clear the system of these 
foreign bodies. An intravenously administered DDS must make its way through a myriad 
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of immune response cellular pathways and blood filtering organs before ultimately 
making it to the targeted tissue.60 The barriers inherent to intravenous injection pose a 
challenge for virtually all intravenously administered DDS. Specifically, the challenge of 
how to effectively dose and get the physical drug to the tissue of concern before the host 
removes them from the body. 
One of the most important factors influencing a DDS’s ability to remain circulating in the 
blood stream is its size.61, 62 Particles smaller than 20 nanometers in diameter will be 
removed from circulation by the reticuloendothelial system (RES) and kidneys within a 
few hours of injection. Particles with a diameter greater than 300 nanometers begin to 
accumulate in the spleen and liver within minutes of injection.58 Therefore, to maximize 
blood circulation time of a drug loaded DDS, the average size of the particles should be 
around 100 nm. This size should be sufficiently large to avoid filtration by the kidneys 
and slow the opsonization process of macrophages in the RES. It also should be small 
enough to avoid being filtered by blood filtration organs like the spleen and liver.63 
Based on these criteria, it is difficult to design a polymeric DDS that can effectively 
shuttle a cargo to a target tissue before it is cleared from the body. First, the rate of 
degradation needs to compete with the rate of clearance of the particles from 
circulation.64 If the rate of degradation is too slow and a significant amount of drug 
remains trapped inside the particles as they are cleared from the blood, incomplete 
administration could occur. Blood circulation times of nanoparticles (NPs) are on the 
order of hours; thus, degradation times need to be on the same timeframe. Second, 
current stimuli-responsive DDSs rely on many stimulating events for complete release of 
cargo. Stimuli-responsive polymers such as those discussed above require a high 
concentration of stimulus due to the many stimulus-polymer interactions required for 
degradation. In target tissues lacking a strong concentration of stimulus, these systems 
may be inefficient at releasing cargo.65 
The development of SIPs could potentially address these difficulties. Self-immolative 
polymeric DDSs respond to low concentrations of specific stimuli leading to rapid release 
of a payload in specific environments.48 This provides an amplified response to stimulus 
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that is lacking in current polymer DDSs. The rapid depolymerization rates of SIPs also 
negates the concern of clearance before the cargo is released.66  
1.3.3 Efficiently Delivering Cargo 
One of the most difficult problems regarding drug development is low solubility of 
hydrophobic drugs in aqueous environments. It has been estimated that 40% of active 
compounds identified through combinatorial screenings show poor water solubility67. 
Poor solubility of hydrophobic drugs leads to complications including variable 
bioavailability, slow onset of action and poor performance. This leads scientists to either 
alter the design of the drug to increase its water solubility or to simply discard the 
molecule all together. Polymeric DDSs aim to increase drug bioavailability and 
effectiveness while also reducing drug toxicity by introducing a method to control 
release.68 Polymer DDSs have proven to be an effective method to overcome the 
difficulty of poorly soluble pharmaceutics. This is accomplished by either encapsulating 
the drug within a hydrophobic polymer nanostructure or covalently binding the drug to a 
water-soluble polymer via labile bonds that can be broken in vivo.69 
NP-based DDSs in particular have emerged as effective methods for overcoming the 
pharmacokinetic limitations of poor solubility and drug toxicity of medicaments. In these 
DDSs, drugs can exist as a reservoir in the circulatory system with drug continually being 
delivered to target tissue over time. Elongated circulation time led to the discovery of an 
important characteristic of tumor cells, the enhanced permeability and retention effect 
(EPR).70 The EPR is a phenomena observed when macromolecules, circulating in the 
blood, demonstrate a heightened accumulation in tumors due to leaky vessels in these 
tissues. This effect gives a passive targeting capability to NP DDSs for the delivery of 
chemotherapeutics to tumors via the blood stream. 
1.3.4 Emulsion Evaporation Technique for Nanoparticle 
Synthesis 
Several methods exist to produce NPs in the range of 10 – 300 nm. For hydrophobic 
homopolymers, the general approach for the preparation of a DDSs is to encapsulate a 
hydrophobic drug within a hydrophobic solid-core polymer particle that is dispersed in 
22 
aqueous solution using surfactants.71 This approach often utilizes the oil-in-water (o/w) 
emulsion-evaporation technique for the manufacturing of polymeric NPs (Figure 12).72  
 
Figure 12. O/W emulsification for the encapsulation of a hydrophobic cargo within solid-core 
polymeric NPs. 
In an o/w emulsion, the hydrophobic polymer is first dissolved in an organic solvent. 
Separately, an amphiphilic surfactant molecule is dissolved in the aqueous phase. The oil 
phase is then added to the water phase and a form of mechanical energy such as stirring 
or ultrasonication is introduced to produce the emulsion. After an emulsion is obtained, 
the organic solvent is evaporated out of the nanodroplets leaving a suspension of polymer 
coated with surfactant dispersed in the aqueous media.73  
The surfactant’s purpose is to serve as a stabilizer between the hydrophobic polymer 
particle with the surrounding aqueous environment. The surfactant allows for the oil 
phase droplets to suspend in the aqueous environment upon formation. The organic phase 
contains the polymer along with the hydrophobic cargo. The organic solvent is then 
slowly removed by evaporation while stirring. After complete removal of the organic 
phase, the particles remain suspended in the aqueous solution by a coating of surfactant. 
1.4 Applications of SIPs in DDSs 
In terms of drug delivery, polymeric NPs have been shown to improve drug targeting 
capabilities, decreasing drug toxicity and increasing efficacy in a variety of different 
hydrophobic therapies.74 These benefits are highly sought after for treatments of certain 
diseases such as cancer with cytotoxic medicaments. Often, a chemotherapeutic is 
administered systemically with the hope that the majority of chemotherapy will make its 
way to infected tissue before it affects healthy tissue. It is unavoidable that some healthy 
tissues will be affected in this method of administration leading to the unwanted side-
effects associated with chemotherapy treatments. Stimuli-responsive polymer NPs have 
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the potential to provide a way to not only target specific areas of the body, but to also 
provide a “smart” characteristic to the drug. Upon encountering a certain stimulus related 
to the target site, the “smart” system will release its cargo.69 
To date, only a handful of SIP systems demonstrating potential for controlled release 
have been reported. The first reported polymeric self-assembling system featuring a SIP 
was by Dewit and Gillies in 2009.41 Their polycarbamate SIP, which was discussed in 
section 1.2.4, was end-capped with poly(ethylene oxide) (PEO) through an ester linkage 
providing an amphiphilic block copolymer. This copolymer was found to self-assemble 
into NPs capable of encapsulating and subsequently releasing a fluorescent dye in 
aqueous solution. This proof-of-concept application opened the door to other stimuli-
responsive SIP delivery systems. 
 In 2010, Moore developed a microcapsule composed of a self-immolative poly(benzyl 
carbamate) (PBC) similar to the polycarbamate reported by Shabat (Scheme 9). Pendant 
protected alcohol moieties were conjugated to the aromatic rings. After polymerization of 
the monomer, the polymer was end-capped with either a fluorenylmethyloxycarbonyl 
(Fmoc) or tert-butyloxycarbonyl (Boc) group. The pendant alcohols were then 
deprotected and converted to isocyanates. From here, microcapsules were synthesized via 
an interfacial polymerization reaction between the isocyanates and 1,4-butanediol.75 To a 
solution containing a surfactant was added the PBC. The PBC was dissolved in 
etheylphenylacetate (EPA), which made up the core of the microcapsules. An emulsion 
was formed between the two solvents and the resulting emulsion was heated at 70 °C for 
1.5 h. Microcapsules in the 5 – 40 µm size range were produced using this method 
(Figure 13).  
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Figure 13. PBC-based core-shell microcapsules. (Reprinted with permission from Moore et. al., 
2010. Copyright 2017 American Chemical Society.)   
 
 
 
Scheme 9. A PBC with pendant tert-butyldimethylsilyl-protected alcohols. 
 
Upon Boc or Fmoc removal by the addition of HCl or piperidine respectively, the 
capsules were degraded. To measure the degradation, the amount of EPA released was 
monitored by gas chromatography. Under these conditions, it was found that close to 
100% of the contents were released within 48 h whereas controls showed less than 10% 
release. 
The Phillip group developed and used PPHA to manufacture microcapsules capable of 
carrying a hydrophilic cargo dissolved in an aqueous environment.45 An improvement to 
the Moore’s method was the use of flow-focusing microfluidics which gives control over 
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the thickness of the microcapsule shell. A microfluidics device used a pump to push a 
water-soluble cargo dissolved in an aqueous, surfactant-containing solution through an 
organic, polymer-containing solvent well. With control of the flow rate, droplets of 
aqueous phase are coated with polymer-containing organic phase. These particles then 
passed through the organic phase into a separate aqueous phase. The microcapsules can 
then be collected and remaining organic solvent evaporated from the shell. PPHA 
microcapsules were made with responsiveness to fluoride by capping the PPHA terminus 
with a silyl ether moiety with similar cargo release rates observed.  
More recently, Liu reported amphiphilic block copolymers that incorporated a 
hydrophobic, polycarbamate SIP block conjugated to a hydrophilic poly(dimethyl 
acrylamide) (PDMA) block (Scheme 10, Figure 14).76 Using self-assembly techniques, 
self-immolative polymersomes (SIPsomes) around 250 nm in diameter were 
manufactured with the capability of encapsulating both hydrophilic and hydrophobic 
cargos. Hydrophilic cargos were dissolved in the aqueous core while hydrophobic cargos 
were encapsulated in the hydrophobic polymer shell. Several stimuli-responsive end-caps 
were used to manufacture SIPsomes capable of triggerable degradation to visible light, 
UV light, and reduction (Scheme 10).    
 
Figure 14. PBC-PDMA multi-block copolymer SIPsomes and their triggerable cargo release. 
(Adapted with permission from Liu et. al., 2014. Copyright 2017 American Chemical Society.) 
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Scheme 10. (a) visible light, (b) UV light, and (c) reduction-sensitive PBCs. 
To take advantage of the dual loading potential of this system for combinational therapy, 
a co-encapsulation of hydrophobic camptothecin (CPT) and hydrophilic doxorubicin 
(DOX) was done. For end-capped polymers responsive to reduction, controls showed 
only ~4% DOX and ~19% CPT released over 20 h.  Upon the addition of 31 mmol 
glutathione (GSH), a biological reducing agent, ~86% DOX and ~82% CPT were 
released over the same timeframe. 
Gillies and coworkers recently showed the promising application of PEtG as a drug 
delivery vehicle.48 The promising advantage of PEtG is that the degradation products 
(i.e., ethanol and glyoxylic acid) have the potential to exhibit low toxicity. PEtG was end-
capped with modified linker end-caps capable of conjugating to PEO to form amphiphilic 
block copolymers. These modified end-caps were still capable of undergoing their 
respective stimuli-responsive reactions, resulting in triggered degradation of the SIP 
blocks. These block copolymers were self-assembled to form micellular NPs capable of 
encapsulating hydrophobic cargos (Figure 15).  
 
Figure 15. Stimuli-responsive NPs based on a triblock SIP. (Reprinted with permission from 
Gillies et. al., 2017. Copyright 2017 American Chemical Society.) 
27 
These particles showed triggerable degradation in response to thiol reducing agents, UV 
light, H2O2 and combinations of these depending on the linker end-caps used. Nile red, 
DOX, and curcumin were all loaded into the particle cores. Their release in response to 
stimulus was measured. The disulfide-capped PEtG showed appreciable payload release 
in concentrations of stimulus, such as dithiothreitol (DTT), as low as 0.1 mM over 48 h 
and close to complete release at higher concentrations of the stimulus (10 mM) over the 
same timeframe. Similar studies were conducted using various responsive end-caps 
concluding triggerable release of cargo with different stimulants simply by altering the 
PEtG end-cap. 
1.5 Thesis Objectives 
The objective of this work was to prepare and study surfactant-coated PEtG solid-core 
particles for drug delivery. In contrast to the NP systems described above, this does not 
require the preparation of block copolymers. The first goal was to optimize conditions for 
generating PEtG NPs. In particular, we targeted a reproducible method providing a mean 
particle diameter (Z-avg.) of ~100 nm for the reasons described above. The size and 
morphology was characterized by dynamic light scattering (DLS) and transmission 
electron microscopy (TEM).  
Additionally, PEtG was blended with varying ratios of PLA. As discussed above, PLA is 
a well-known and established biocompatible and biodegradable polymer. It was 
hypothesized that the addition of this polymer to create PLA-PEtG blends would increase 
the hydrophobicity and rigidity of the NP cores allowing for tunable rates of release to 
this DDSs based on wt% PLA. Each PLA-PEtG blend was characterized by 
thermogravimetric analysis (TGA) and differential scanning calorimetry (DSC) in order 
to determine the phase separation behavior of these polymers. 
After determination of the synthetic route and characterization of these particles, the 
focus shifted toward testing the stimuli-responses behavior of these solid-core PLA-PEtG 
particles. A fluorescent small molecule was used as a molecular probe to test for 
triggerable release of a hydrophobic cargo. Furthermore, a model drug was encapsulated 
and the release kinetics studied. Investigation into the optimal loading efficiency and 
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percent weight cargo was determined for drug-loaded PLA-PEtG NPs. Triggerable 
release was tested using a UV-responsive end-cap. This end-cap serves as an ideal model 
system as it can be cleanly and rapidly removed by irradiation with UV light. However, 
in most applications, it would not be possible to apply UV light in vivo. Therefore, to 
further investigate the possibility of triggering release using biologically accessible 
triggers, an end-cap responsive to reducing agents was also investigated as a potential 
triggerable end-cap. 
Finally, the triggerable release of drug-loaded PLA-PEtG NPs was tested in vivo in 
MDA-MB-231 cells. 3-(4,5-dimtheylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) assays will be conducted to test for viability of this cell line treated with drug-
loaded PLA-PEtG particles.  
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2 Experimental 
2.1 General Procedures and Materials 
6-Nitroveratryl carbonate end-capped poly(ethyl glyoxylate) (NVOC-PEtG) (Mn = 
70,000 g/mol, Ð = 2.4), benzyl carbonate end-capped poly(ethyl glyoxylate) (BnCO-
PEtG) (Mn = 56,000 g/mol, Ð = 1.6), 2-(pyridine-2-yl-disulfanyl)ethyl carbonate end-
capped poly(ethyl glyoxylate) (disulfide-PEtG) (Mn = 24,000 g/mol, Ð = 1.4) were 
prepared as previously reported.46 All other chemicals were obtained from commercial 
suppliers and used without further purification. TGA was performed on a Q50 from TA 
Instruments with the following conditions: heat rate of 10 °C/min ranging from 35−500 
°C under nitrogen atmosphere. Size-exclusion chromatography (SEC) was performed in 
THF at 1 mL/min using a viscotek GPC Max VE2001 solvent module equipped with a 
Viscotek VE3580 RI detector operating at 30 °C, two Agilent Polypore (300x7.5mm) 
columns, and a Polypore guard column (50x7.5mm). A calibration curve was obtained 
using polystyrene standards. Fluorescence spectra were obtained using a QM-4 SE 
spectrometer from Photon Technology International equipped with double excitation and 
emission monochromators. UV-visible spectra were obtained on a Varian UV/Vis Cary 
300 spectrophotometer. Centrifugation was performed using a Clinical 200 VWR 
centrifuge at 6000 rpm. Ultrapure water was obtained from a Barnstead EASYpure II 
system. Sonication was conducted using a Branson 450 digital sonifier. Spectra/Por 
regenerated cellulose membranes were used for dialysis. 0.22 µm Acrodisc Syringe Filter 
Non-Pyrogenic 13 mm were used to filter all particle suspensions. 
2.2 Preparation of Poly(ethyl glyoxylate)-poly(D,L-lactic 
acid) Blends 
Poly(ethyl glyoxylate)-poly(D,L-lactic acid) (PLA-PEtG) blends were made by 
combining 9.0, 7.0 and 5.0 mg PEtG with 1.0, 3.0 and 5.0 mg, respectively, of PLA to 
obtain blends that were 10, 30 and 50 wt% PLA. These polymer samples were then 
dissolved in dichloromethane (1 mL) and stirred for 30 min to allow for complete mixing 
of the polymers.77 The solvent was removed in vacuo for analyses. 
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2.3 Method for Preparing Nanometer-sized Particles 
PEtG (10.0 mg) was dissolved in dichloromethane (1 mL). A separate solution of sodium 
cholate (50 mg) was prepared in distilled water (10 mL) for a final concentration of 12 
mM. The organic phase was added to the aqueous phase by glass pipette into a 20 mL 
glass vial. The sonication amplitude was set to 10% on a Branson 450 digital sonifier. 
The biphasic mixture was then sonicated for three 30 s intervals with 10 s breaks in 
between for a total of  90 s of sonication over 120 s.78 To the resulting emulsion mixture, 
a magnetic stir bar was added and the solution was vigorously stirred overnight (16 h) to 
evaporate the organic phase. After evaporation of the organic phase, the particle 
suspension was dialyzed (3,500 g/mol molecular-weight cut-off (MWCO) dialysis 
membrane, 8 h) against distilled water to remove any excess sodium cholate. The particle 
suspension was then passed through a 0.22 μm syringe filter. 
To create PLA-PEtG blended NPs, select weight percentages of PLA were incorporated 
into the PEtG organic phase. Specifically, 10 wt%, 30 wt% and 50 wt% PLA-PEtG 
blends were prepared as described above. The dichloromethane solutions of these blends 
were added to the aqueous phase, then the biphasic mixture was sonicated, dried and 
dialyzed and the resulting particles were dialyzed by the methods described above.   
2.4 Dynamic Light Scattering 
DLS was performed using a Zetasizer Nano ZS instrument from Malvern Instruments at 
25 °C at a concentration of 0.1 mg/mL of polymer assemblies. The Z-average diameter 
and polydispersity index for each series of particles was measured in triplicate.   
2.5 Preparing Particles for Imaging 
TEM imaging was done using a Phillips CM10 microscope operating at an acceleration 
voltage of 80 kV with a 40 µm aperture. 20 µL of particle suspension (1.0 mg/mL) was 
placed on a copper grid. The resulting sample was air-dried for 24 h before imaging.   
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2.6 NP Degradation Studied by DLS 
NPs were prepared as above, with the exception that the suspensions were dialyzed 
against 100 mM, pH 7.4 phosphate buffer (1 L, 24 h, water changed once at ~12 h). The 
polymer concentration was 0.1 mg/mL. The count rate was measured by DLS while 
fixing the attenuator at 7. For NVOC-PEtG and BnCO-PEtG, irradiation with UV light 
was performed in an ACE Glass photochemistry cabinet containing a mercury light 
source (450 W bulb, 2.8 mW/cm2 of UVA radiation) for 30 minutes. For disulfide-PEtG 
and the BnCO-PEtG control, DTT (7.7 mmol) was added. Control experiments without 
stimulus were also included in each case after applying the stimulus, the samples were 
incubated at 37 °C in the dark and the DLS count rate was measured at selected time 
points. Each experiment was performed and studied in triplicate.  
2.7 Loading and Release of Nile Red 
Nile red-loaded NPs were prepared by the addition of Nile red (0.1 mg, 0.03 mmol) to the 
organic phase containing defined weight percentages of PEtG and PLA. The organic 
phase was allowed to stir for several hours to facilitate complete mixture of the blends 
and Nile red. The polymer-Nile red solution was added to the surfactant-containing 
aqueous phase and subjected to sonication, as described above. After sonication and 
evaporation, the particle suspensions were dialyzed against water using a 3,500 g/mol 
MWCO dialysis membrane for 24 h to remove excess surfactant and any trace 
unencapsulated Nile red.  
To test for triggerable release of Nile red from the particles, NPs were again prepared as 
above with 0.1 mg Nile red added to the organic phase. The particle suspensions were 
dialyzed against 100 mM, pH 7.4 phosphate buffer. After 24 h of dialysis, the solutions 
were diluted 10-fold in pH 7.4 phosphate buffer to yield a Nile red concentration (3 µM) 
within the detectable range of the fluorimeter. Using an excitation wavelength of 540 nm, 
the initial emission intensity of Nile red was measured at 602 nm to obtain fluorescence 
at T0 (starting time). At this point, the appropriate stimulus (UV light for NVOC-PEtG 
and DTT for disulfide-PEtG) was added, or not added in the case of controls, and the 
solutions were placed in a 37 °C oven. Fluorescence measurements were taken at 
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incremental time points over a 24 h period. By comparing the fluorescence at each time 
point with its initial fluorescence, the percent initial fluorescence was calculated. These 
measurements were taken in triplicate and conducted for each of the three polymer 
blends.   
2.8 Preparation of Letrozole-Loaded NPs 
NPs were prepared as above with the addition of letrozole (30 wt%, 3 mg, 0.86 mmol) 
dissolved in the organic phase with the polymer mixtures before sonication. After 
sonication, the suspensions were again dialyzed in a 3,500 g/mol MWCO membrane for 
24 h to remove any unencapsulated letrozole. After dialysis, the solutions were passed 
through a 0.22 μm syringe filter and a portion was lyophilized to calculate the loading 
efficiency and drug wt%. The lyophilized pellet was weighed and then dissolved in 1 mL 
of acetonitrile. The absorbance of the resulting solution was measured by UV-visible 
spectroscopy at 240 nm. The concentration was calculated based on a letrozole 
calibration curve (ɛ = 30,600 L/mol·cm, acetonitrile) and the loading efficiency and drug 
content of the NPs was calculated as followed: 
𝐿𝑜𝑎𝑑𝑖𝑛𝑔 𝐸𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 =
𝐷𝑟𝑢𝑔 𝐸𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑒𝑑
𝐷𝑟𝑢𝑔 𝐿𝑜𝑎𝑑𝑒𝑑
 ×  100 
𝐷𝑟𝑢𝑔 𝑤𝑡% =
𝐸𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑒𝑑 𝐷𝑟𝑢𝑔 𝑀𝑎𝑠𝑠
𝑇𝑜𝑡𝑎𝑙 𝑀𝑎𝑠𝑠
 ×  100 
2.9 Triggerable Release of Letrozole   
For drug release studies, NPs were prepared as described above with the exception that 
after sonication and evaporation, the particle suspensions were dialyzed against 100 mM, 
pH 7.4 phosphate buffer (1 L, 16 h, dialysate exchanged at ~8 h) using a 3,500 g/mol 
MWCO membrane to remove any unencapsulated letrozole and excess surfactant. The 
particles were then filtered through a 0.22 µm syringe filter and diluted 10-fold with 100 
mM, pH 7.4 phosphate buffer. An initial absorbance measurement was taken (T0). 
Subsequently, the appropriate stimulus was introduced as described above for the DLS 
experiments. The samples were then each placed in an individual 3,500 g/mol MWCO 
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dialysis membrane and dialyzed in 7.4 phosphate buffer in a 37 °C oven. To measure the 
letrozole release rates, 200 µL of each sample were taken at incremental time points and 
passed through a 0.22 µL syringe filter. From the filtered solution, three 50 µL aliquots 
were taken and diluted into 1 mL of acetonitrile to fully dissolve the polymer particles 
and remaining encapsulated drug. The absorbance was measured at 240 nm (ɛ = 30,600 
L/mol·cm). Release rates were obtained by plotting the absorbance at each time point as a 
percentage of initial absorbance. 
2.10 Triggerable Release of Celecoxib 
For celecoxib release studies, disulfide-PLA-PEtG and BnCO-PEtG NPs were prepared 
as described above and dialyzed against 100 mM, pH 7.4 phosphate buffer (1 L, 16 h, 
dialysate exchanged at ~8 h) using a 3,500 g/mol MWCO membrane to remove any 
unencapsulated celecoxib and any excess surfactant. They were then filtered through a 
0.22 µm syringe filter and diluted 10-fold with 100 mM, pH 7.4 phosphate buffer. An 
initial absorbance measurement was taken by removing 200 µL of each sample and 
dissolving it in 1 mL acetonitrile. The absorbance was measured at 253 nm (ɛ = 16,400 
L/mol·cm for celecoxib based on a calibration curve in the same medium) in order to 
quantify the total amount of drug initially encapsulated in the system. Subsequently, the 
appropriate stimulus was introduced as described above for the reduction-responsive DLS 
experiments. The samples were then each placed in an individual 20 mL vial with a small 
bar magnet, stirred at low rpm and kept in a 37 °C oven for the duration of the study. At 
distinct time points, each sample was centrifuged for three minutes at 6,000 rpm to 
separate the precipitated drug from the particles and encapsulated drug that remained 
suspended in the medium. The suspension was decanted back into the initial vial and 
placed back into the oven while the pellet was dissolved in 1 mL acetonitrile and the 
absorbance at 253 nm was taken to quantify the amount of drug that had been released 
and consequently precipitated. This amount was compared to the initial amount of 
encapsulated drug in order to determine the percentage of released drug. 
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2.11 Cell Toxicity Study 
Dulbecco’s modified Eagle medium (DMEM) with 4.5 g/L D-glucose and 110 mg/L 
sodium pyruvate was obtained from Gibco. Penstrep, 10% fetal bovine serum (FBS) and 
trypsin-EDTA (0.25%) were obtained from Gibco. The MDA-MB-231 cells were 
cultured in DMEM with 10% FBS and 100 units/mL of Penstrep in an atmosphere of 5% 
CO2 at 37
 °C. The cells were seeded in a 96 well plate (Corning Flat Bottom Plate) at a 
concentration of 5,000 cells/well. Cells were placed in an incubator for 24 h (37 °C, 5% 
CO2). Following the incubation, the medium was aspirated and replaced with various 
treatments of NPs of 1, 0.5, 0.25, 0.13, 0.06 mg/mL. For UV-sensitive particle studies, 
the cells were irradiated with 30 minutes of 360 nm light using light emitting diode 
flashlights. Negative controls include either just media or the test material. The cells were 
then incubated at 37 oC for 48 h. The medium was then aspirated and replaced with 100 
µL of fresh medium containing 0.5 mg/ml (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) (MTT) reagent and allowed to react for 4 h in the incubator 
at 37 °C. After 4 h the plate was removed and the MTT reagent solution was aspirated. 50 
µL of dimethyl sulfoxide was added to each well to solubilize the metabolic reagent of 
MTT. The plate was then placed in a plate reader (Tecan Infinite M1000 Pro, absorbance 
540 nm) to obtain cell counts. No biological replicates were performed; six technical 
replicates were performed per treatment.  
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3 Results & Discussion 
3.1 Stimuli-Responsive Poly(ethyl glyoxylate) Synthesis 
PEtG was synthesized as previously reported (Scheme 11).46 The purity of ethyl 
glyoxylate monomer was the limiting factor on the molecular weight of PEtG. The 
monomer was purchased as a 50:50 volume ratio in toluene. After two distillations over 
phosphorus pentoxide (P2O5) as a drying agent, pure monomer was obtained. The 
monomer was cooled to −20 °C and polymerization initiated by adding a catalytic 
amount of TEA. The mechanism of polymerization is hypothesized to be initiated from 
trace amounts of hydrated monomer. After polymerization, the polymer was held at −20 
°C and the desired chloroformate-functionalized end-cap was added. In this work, 
polymers with three different stimuli-responsive end-caps were prepared: NVOC-PEtG, 
which is responsive to UV light; disulfide-PEtG, which is responsive to reducing agents 
such as DTT; BnCO-PEtG, which is non-responsive and serves as a control. The molar 
mass data for the polymers used in this work is shown in Table 1. 
 
Table 1. Average molecular weight (Mn) and polydispersity of end-capped PEtG used. 
polymer Mn (SEC) (g/mol) Ð To (°C) 
NVOC-PEtG 70,000 2.4 203 
disulfide-PEtG 24,000 1.4 191 
BnCO-PEtG 56,000 1.6 162 
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Scheme 11. Synthesis of different classes of PEtGs. 
 
3.2 Emulsion Optimization 
3.2.1 Determination of Optimal Surfactant Concentration 
One of the most common surfactants used in NP research has been PVA due to its 
biocompatibility and non-toxicity.61 However, previous work done by the Gillies group 
determined that PVA used as the surfactant for PEtG emulsion methods gave particles 
diameters of 400 nm -  too large to be optimal for intravenous drug delivery.74 Further 
research on appropriate surfactants concluded that PEtG NPs stabilized with sodium 
cholate as the surfactant could be manufactured with particle sizes of 120 nm.79 Cholic 
acid (3α,7α-trihydroxy-5β-cholan-24-oic acid) is a primary bile acid produced by the 
liver. The sodium or potassium salts of cholic acid are water dispersible and are naturally 
used by the body in its digestion of fats and oils. Therefore, sodium cholate can act as a 
biocompatible surfactant for NPs.80 
37 
Parameters of the O/W emulsion technique were investigated with efforts focused on 
preparing particles with diameters in the 100 nm range.81 The two variables found to 
contribute the most towards controlling the diameter were surfactant:polymer ratio and 
sonication time. As the particles get smaller, their surface area increases which increases 
the overall oil-water interactions. Therefore, to get smaller particles, higher 
concentrations of surfactant were required. To determine the appropriate 
surfactant:polymer ratio, the concentration of PEtG was kept constant (1 mg/mL) while 
varying the surfactant concentration from 0 mg/mL to 100 mg/mL. The biphasic mixture 
was subjected to two minutes of sonication and the resulting emulsion was dried and then 
dialyzed in distilled water as described above. The particle diameter was then measured 
by DLS. As expected, 0 mg surfactant led to precipitation of polymer after evaporation. 
As the surfactant concentration increased, the diameter of the particles decreased (Figure 
16).  
 
Figure 16. Concentration of sodium cholate vs. Z-avg. while the concentration of PEtG was kept 
constant at 1 mg/mL. 
Although a meaningful change in the Z-avg. was not detected by measuring the diameter 
of these systems, at low concentrations of surfactant, significant precipitation of polymer 
was observed. This can be attributed to the necessity of a high concentration of surfactant 
for small particles due to the high surface area. A sodium cholate concentration of 12 mM 
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was found to yield the desired particle diameter with no appreciable precipitation of 
polymer. This gave a surfactant:polymer weight ratio of 5:1. 
3.2.2 Determination of Optimal Sonication Time 
The second major factor in controlling the particle diameter was the sonication time. To 
examine the effect of the sonication, the relationship between sonication time to particle 
diameter was studied. The PEtG concentration was fixed at 1 mg/mL as above, and the 
sodium cholate concentration was fixed at 5 mg/mL. The two solutions were combined 
and emulsified using sonication for varying lengths of time. The resulting emulsion was 
then stirred overnight and purified by dialysis as above. The resulting particles were 
measured using DLS to determine the Z-avg. It is known that prolonged shearing forces 
introduced by sonication can cleave polymer backbones over time. With the relatively 
labile polyacetal backbone of PEtG, it was important to find the minimum amount of 
sonication time needed to produce NPs close to 100 nm (Figure 17).82 The data showed 
significant decrease in particle size up to approximately 90 s. After that, the particle size 
appeared to not change significantly with increased sonication time. With this data, along 
with results presented in Figure 16, all particle batches going forward were performed 
under Table 2 conditions. 
 
Figure 17. Emulsion sonication time vs. Z-avg. for PEtG NPs while keeping the concentration of 
PEtG constant at 1 mg/mL and sodium cholate concentration at 5 mg/mL. 
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Table 2. Emulsification conditions for the production of 100 - 150 nm-sized PEtG-based NPs. 
Sodium Cholate 
(mg) 
PEtG 
(mg) 
D.I. H2O 
(mL) 
CH2Cl2 
(mL) 
Sonication Time 
50 10 10 1 
3 rounds (30 s) with  
intervals (10 s) 
3.2.3 PLA-PEtG Polymer Blend Characterizations 
PEtG was anticipated to provide rapid release upon stimulation. To provide further 
control and tuning of the release properties, PEtG was blended with varying weight 
percentages of PLA. It was anticipated that the PEtG phases of NPs would provide a 
burst release at the target, while the polyester domains would afford continual slow 
release as these domains would degrade more slowly. The presence of a non-stimuli-
responsive polymer would lead to increase in overall degradation time which may lead to 
tunability of cargo release. Specific weight percentages of PLA were substituted for 
PEtG. Blends of 0 wt%, 10 wt%, 30 wt%, 50 wt%, and 100 wt% PLA were prepared by 
dissolving the two polymers in dichloromethane. 
Characterization of each polymer blend was conducted using both thermogravimetric 
analysis (TGA) and differential scanning calorimetry (DSC). TGA data showed two-step 
thermal degradation in the three blends and the blend ratios were consistent with the 
incremental weight percentages of PLA present in each sample (Figure 18). Pure PLA 
matched literature values of degradation temperatures showing PLA stable up to 300 
°C.83 The PEtG sample matched reported values of 180−200 °C for end-capped PEtG.46 
The addition of PLA appears to stabilize PEtG in some way. This can be seen by the 
increase in onset degradation temperature (To) of PEtG in each of the three blends. The 
degradation of PEtG increased about 100 °C by the incorporation of 10 wt% and 30 wt% 
PLA, and even more so with 50 wt% PLA. This could be due to favorable intermolecular 
forces between regions of the two polymers. 
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Figure 18. TGA data for the PLA-PEtG blends. 
DSC data showed the two polymers were mostly phase separated in the blends (Figure 
19). This can be seen from the two distinct glass transition temperature (Tg) values 
arising from the two different polymers (Table 3). The Tg for PEtG can be clearly seen for 
each blend and matches the literature value of about −5 °C.  There may be some slight 
miscibility between these two polymers because the reported Tg for PLA is 50 °C, but the 
Tg values for PLA in the blends range from 41 to 46 °C. In addition, the Tg of PEtG 
increased from −8 °C for the pure PEtG to −1 °C for the 50% PLA blend. 
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Figure 19. DSC thermograms recorded for pure PEtG, pure PLA and the three blends. 
 
Table 3. Tgs recorded for the PLA-PEtG blends. 
The immiscibility of these polymers suggests microphase separation of the polymers. 
When PEtG is degraded, a porous PLA scaffold should be left which will rely on random 
hydrolysis to degrade completely. The phase separation suggests an initial burst release 
of cargo followed by a slower release of residual cargo encapsulated within the remaining 
PLA scaffold. The burst release would then be incrementally less with increasing PLA 
content, while the fraction undergoing slow release should increase. With a better 
understanding of the nature of these polymer blends in hand, the synthesis of these 
particles with their varying blends was investigated and their properties analyzed. 
Blend PEtG Tg (°C) PLA Tg (°C) 
100% PEtG −7.6 - 
10% PLA −5.3 43.6 
30% PLA −3.2 40.8 
50% PLA −1.1 39.8 
100% PLA - 46.0 
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3.3 Characterization of Particles 
3.3.1 Characterization of Particles by DLS 
The first method of characterization performed was the determination of the Z-avg. The 
diameter for each blended batch of particles was determined using DLS. Each particle 
suspension was prepared using conditions described earlier (section 3.2.2). Subsequently, 
the particle suspensions were diluted to 0.1 mg/mL with distilled water to give 
appropriate concentrations for DLS. In Figure 20 data are presented for the five blend 
compositions. The Z-avg. diameters ranged from 128–144 nm and did not change 
significantly with the incorporation of PLA. The PDI values ranged from 0.03–0.26, 
which is considered relatively low. A summary of these DLS diameter distributions is 
shown in Table 4.  
 
Figure 20. Representative DLS diameter distributions of the PLA-PEtG blends: (a) intensity 
distributions and (b) volume distributions. 
 
 
 
43 
Table 4. Z-avg. and polydispersity indices for the PLA-PEtG blends. 
Blend Z-avg. (nm) PDI 
0% PLA 144 ± 13 0.19 ± 0.07 
10% PLA 137 ± 19 0.26 ± 0.11 
30% PLA 128 ± 7 0.11 ± 0.03 
50% PLA 133 ± 8 0.12 ± 0.03 
100% PLA 132 ± 10 0.13 ± 0.04 
3.3.2 Characterization of Particles Using Transmission 
Electron Microscopy 
With understanding of the blend characteristics and particle diameters in hand, it was 
important to image the particles to confirm the morphologies and the particle diameters. 
Due to the inability to freeze dry low PLA-content particles because of the low Tg of 
PEtG, scanning electron microscopy (SEM) proved difficult as the particles tended to 
fuse together. Therefore, TEM was employed as the imaging technique for the particles. 
Using this imaging technique, samples prepared from particle suspensions could be 
made, bypassing the need to freeze dry.   
Figure 21 shows images for pure PEtG particles and those prepared from each of the 
three blends. The particle diameters observed by TEM were in general smaller than those 
measured by DLS. The observation of smaller diameters in TEM imaging is quite 
common, as TEM measures the samples in their dehydrated state whereas DLS measures 
the samples in their hydrated state. In agreement with the DLS results, increasing the 
PLA content to 30 wt% (Figure 21c) and 50 wt% (Figure 21d) does not seem to 
destabilize the morphology of the particles even though the two polymers are immiscible. 
The particles in these samples appear to be spherical and monodisperse. 
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Figure 21. Transmission electron micrographs of NPs prepared from (a) 100% PEtG, (b) 10 wt% 
PLA, (c) 30 wt% PLA, (d) 50 wt% PLA. 
3.4 Triggerable Degradation Studies 
3.4.1 Degradation Measured by DLS 
After it was concluded that PEtG could be successfully blended with PLA and made into 
relatively monodisperse NPs, investigating the triggerable degradation nature of these 
particles was the next step. In addition to NVOC-PEtG which was used for the above 
work, particles were prepared from disulfide-PEtG and BnCO-PEtG by the same method 
described above. Changing only the end-cap did not lead to any significant changes in the 
particle diameter or morphology as determined by DLS and TEM (Figures A-3 – A-5 in 
the appendix). 
DLS was employed to test for degradation of particles in response to stimuli. This 
technique can be used to probe for particle degradation because the count rate is 
proportional to both the number of particles in suspension as well as their size. A 
decrease in either the size or number of particles arising from degradation would lead to a 
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reduction in the count rate. The appropriate concentration for the DLS studies of the 
particle suspensions was found to be 0.1 mg/mL. Keeping the attenuator fixed, the light 
scattering count rate was measured initially and then at various time points after 
introduction of the stimulus. Control experiments involved application of the stimulus to 
non-responsive BnCO-PEtG particles to account for any non-specific effects on the 
particles. Each ratio of PEtG:PLA was studied.  
Figure 22 shows the response of the NVOC-PEtG and BnCO-PEtG (PEtG-control) 
particles to 30 minutes of UV irradiation. Two important observations came from this 
study. First, for each PEtG:PLA ratio of NVOC-PEtG particles there is a rapid decrease 
in count rate over the first hour following UV irradiation that likely corresponded to 
degradation of particles. On the other hand, the scattered light intensity from the BnCO-
PEtG control particles stayed relatively constant at 100% of their initial count rate over a 
24 h period. Secondly, with increasing PLA content in the particles, there was a plateau 
of the degradation which corresponded approximately to the amount of PLA in the 
particles. Pure PEtG particles appeared to approach zero counts at the 24 h time point, 10 
wt% particles degraded to roughly 10% of their original count rate and then remained 
constant, 30 wt% plateaued at 30% of the initial count rate and 50 wt% PLA particles 
plateaued at 50% of the initial count rate. Also, light scattered from the pure PLA 
particles remained constant at 100% original counts over the 24 h period.  
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Figure 22. % Initial scattering count rate (DLS) vs. time for NVOC-PEtG and BnCO-PEtG 
control particles following UV irradiation for 30 min. 
To demonstrate the system can show responsiveness to several different stimuli just by 
changing the end-cap, the study was repeated for disulfide-PEtG, which contains an end-
cap susceptible to reduction through its disulfide linkage. The reducing agent used to 
trigger the end-cap was DTT. Figure 23 shows the DLS count rate over a period of 48 h 
following the addition of 7.7 mmol DTT to the particles. It was observed that overall, the 
reduction in count rate occurred more slowly than for the NVOC-PEtG particles in the 
UV study. There are two factors that may be causing this: 1) the UV reaction could 
proceed at a faster rate than the reduction reaction; 2) the DTT is limited by only being 
able to react with surface end-cap groups first allowing fewer reactions to occur 
simultaneously whereas UV light can penetrate past the surface. Again, the particles 
containing less PLA underwent larger reductions in the count rate over the experiment, 
likely corresponding to more complete degradation. The scattered light intensities from 
the PEtG-control and pure PLA particles all remained near 100% of their original values.  
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Figure 23. % Initial scattering count rate (DLS) vs. time for disulfide-PEtG and BnCO-PEtG 
control particles following the addition of 7.7 mmol DTT. 
Overall, the data collected for both NVOC-PEtG and disulfide-PEtG show that it is 
possible to trigger degradation of the particles specifically by matching the stimulus with 
the end-cap and that it appears possible to trigger different percentages of degradation by 
tuning the PLA content in the particles. 
3.4.2 Triggerable Release of a Fluorescent Probe 
As an initial study to test for triggerable release of an encapsulated cargo, a fluorescent 
cargo molecule was used as a probe. The same conditions were used as for the DLS study 
where NVOC-PEtG particles were used as the UV-light responsive particles and 
disulfide-PEtG were used as reduction responsive particles. BnCO-PEtG particles were 
again used as a non-stimuli responsive control. Nile red dye was selected as an 
appropriate proof-of-concept cargo. Nile red can be loaded at low concentrations which 
allows for effective probing of triggerable release of cargo by measuring fluorescence of 
particle suspensions at incremental time points post-stimulus exposure. In hydrophobic 
environments, Nile red is highly fluorescent, while, in hydrophilic environments, Nile red 
undergoes aggregation and its fluorescence is significantly quenched.84 Therefore, Nile 
red encapsulated within PEtG NPs will fluoresce and as it is released into the surrounding 
aqueous environment, the fluorescence will decrease.   
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Nile red encapsulated NPs were prepared by the same method described above except 
that 2 wt% of Nile red relative to polymer was incorporated into the dichloromethane 
phase to load the particles. Batches were made for each of the PLA weight percentages as 
above, including pure PEtG and pure PLA. Qualitatively, the fluorescence of Nile red in 
different hydrophobic environments can be seen in Figure 24.  The far-right vial (24e) 
contains the 100% PLA Nile red-loaded particles. This represents the most hydrophobic 
environment for the Nile red and this is seen by the intensity of the color.85 Moving to the 
left are NVOC-PEtG samples with decreasing wt% PLA. With decreasing wt% PLA in 
the particles, the intensity of the color drops off with each incremental decrease of PLA. 
This further supports the different environments present in the cores of the different PLA-
PEtG blended particles. The PLA adds hydrophobic character to the particles, whereas 
the PEtG is more hydrophilic which could help facilitate more Nile red encapsulation in 
the particles with the higher PLA content, leading to a more intense color. 
 
Figure 24. Nile red-loaded PLA-PEtG NP suspensions: (a) 100% PEtG, (b) 10 wt% PLA, (c) 30 
wt% PLA, (d) 50 wt% PLA, and (e) 100% PLA. 
The initial fluorescence intensity was measured for each sample along with controls. 
During the duration of the study, the samples were kept in a 37 °C oven in 100 mM, pH 
7.4 phosphate buffer. Each successive time point following application of the stimulus 
was measured as a percent of initial fluorescence. An example of these data taken for 0% 
PLA NVOC-PEtG is shown in Figure 25. The graph tracks the fluorescence from T0, 
which was taken for NVOC-PEtG particles prepared with 100% PEtG before UV-light 
exposure up to 60 minutes after exposure. The data can further be processed to plot a 
percent initial fluorescence over time by taking the maximum value for each time point as 
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a percentage of the initial fluorescence (Figure 26). Using these data allows for 
comparison between the different weight percentage PLA-PEtG particles and their Nile 
red release rates. 
 
Figure 25. Fluorescence emission spectra of Nile red-loaded 100% NVOC-PEtG NPs over a 
period of 1 h post-UV exposure. 
 
Figure 26. Fluorescence behavior of Nile red-loaded 100% NVOC-PEtG NPs. 
The Nile red fluorescence experiments were conducted for both UV light-responsive and 
reduction-responsive particles using NVOC-PEtG and disulfide-PEtG, along with BnCO-
PEtG control NPs for each stimulus. The fluorescence changes over time following 
application of the stimulus for the different PEtG:PLA ratios are shown in Figure 27 for 
UV light and Figure 28 for DTT as a stimulus. The findings correspond with previous 
0%
20%
40%
60%
80%
100%
0 5 10 15 20 25
%
 In
it
ia
l F
lu
o
re
sc
e
n
ce
Time (h)
NVOC-PEtG BnCF-PEtG non-irradiated NVOC-PEtG
50 
experimental results from the DLS degradation studies. Specifically, these data show that 
the NVOC-PEtG particles exhibited a significant burst release of Nile red within the first 
hour after being exposed to UV light. This is due to the PEtG fraction of the particles 
being degraded. Each different PLA wt% then plateaued at a different value, 
corresponding to the remaining PLA in the particles. In other words, a percentage of the 
particle’s hydrophobic core remained, which was still able to encapsulate Nile red within 
a hydrophobic environment. Figure 28 shows that the release of Nile red following 
application of DTT to the disulfide-PEtG NPs was slower than for the light-responsive 
particles. As for the DLS study, this can likely be attributed to slower end-cap cleavage. 
As for the NVOC-PEtG particles, increasing the PLA content resulted in a higher 
retention of Nile red. In each experiment, the controls of BnCO-PEtG particles with 
applied stimuli showed a 10 – 20% reduction in Nile red fluorescence, which can likely 
be interpreted as passive diffusion of Nile red from the periphery or edges of the 
particles.  
 
Figure 27. Fluorescence emission behavior observed at different time intervals for NVOC-PEtG 
and BnCO-PEtG control particles with varying PLA content after the UV light irradiation (30 
min).  
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Figure 28. Fluorescence emission behavior observed at different time intervals for disulfide-
PEtG and BnCO-PEtG with varying PLA content after the addition of DTT. 
In terms of controlling the release of Nile red, UV light as a stimulus did not give 
significant control over the burst release. After exposure to UV light, each particle 
suspension resulted in a quick burst release consistent with the corresponding PLA 
content, followed by a slower rate of release from the PLA regions. There does however 
appear to be some control over where the slower, plateau region occurs by varying the 
wt% of PLA content in these particles. Using 7.7 mmol DTT as a stimulus led to a better 
control in the burst release. The difference can be seen in the 100% PEtG sample that 
took 24 h to release 80% of the Nile red compared to the UV sample that took less than 1 
h to release the same amount. Due to this slower release profile, the plateau regions in the 
DTT-responsive data are not as apparent. 
3.5 Hydrophobic Cargo Encapsulation and Release 
3.5.1 Characterization of Drug-Loaded PLA-PEtG NPs 
The DLS studies, along with the Nile red studies, provided sufficient proof of concept for 
triggerable degradation of PEtG NPs. The next step was to load the particles with a model 
drug and test for triggerable release of this drug.86 A common literature procedure for 
these studies involves encapsulating a UV active drug molecule within the DDS and 
placing the particle suspensions in dialysis. Using a drug that absorbs UV or visible light 
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above ~210 nm, the drug release can be tracked by taking UV-Vis spectroscopy 
measurements of the dialysate or the suspension within the dialysis membrane over time 
to obtain a release profile. Several hydrophobic drugs were investigated as potential 
candidates for encapsulation and drug release. The loading efficiency and drug content 
calculations were made for each drug and are summarized in Table 5. Surprisingly, the 
four different drugs tested had starkly different loading efficiencies and drug contents. 
Curcumin, an herbal supplement, showed the worst encapsulation efficiency at 21% with 
a drug content of only 3%. The most successful candidate was celecoxib, an anti-
inflammatory medication. Celecoxib had a loading efficiency of 77% and a 25% drug 
content. Letrozole, used to treat breast cancer, and DOX, a common chemotherapy, were 
also tested with moderate loading efficiencies of 44% and 38% respectively. Based on the 
loading efficiencies and drug content of these four candidates, letrozole and celecoxib 
were chosen as the two drugs for further studies. 
Table 5. Drug loading properties of 30% PLA-PEtG NPs. 
Drug Structure 
Loading 
Efficiency 
Drug Content 
(wt%) 
λmax 
(nm) 
Letrozole 
 
44 ± 5% 17 ± 2% 240  
Celecoxib 
 
77 ± 9% 25 ± 3% 253  
Curcumin 
 
21 ± 3% 3 ± 1% 524  
Doxorubicin 
 
38 ± 7% 22 ± 4% 485  
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PLA-PEtG NPs containing letrozole were characterized using DLS and TEM to examine 
any differences between loaded and unloaded particles in terms of average diameter and 
morphology. In Figure 29 and Table 6 data collected for unloaded PLA-PEtG particle 
diameters from DLS studies were compared with those collected for their respective 
loaded counterparts. Drug-loaded particles were similar in size to unloaded particles, but 
significantly larger diameters (p < 0.05) were observed for 100% PEtG, 30% PLA-PEtG, 
50% PLA-PEtG and 100% PLA particles. The PDIs for the loaded particles were also 
significantly larger for 30% PLA-PEtG particles. However, loaded particles were well 
below the 300 nm cutoff for maximum particle diameter and the PDIs were all below 0.3, 
which is the benchmark for uniformity in size. 
Table 6. Size specifications of the letrozole-loaded/unloaded particles based on PLA-PEtG 
blends. (Standard Error, n = 3) 
 Loaded Unloaded* 
Blend 
DLS Z-avg. 
(nm) 
PDI 
DLS Z-avg. 
(nm) 
PDI 
100% PEtG 144 ± 9 0.16 ± 0.06 114 ± 9 0.19 ± 0.07 
10% PLA-PEtG 137 ± 21 0.29 ± 0.10 127 ± 19 0.28 ± 0.11 
30% PLA-PEtG 128 ± 16 0.22 ± 0.04 118 ± 7 0.11 ± 0.03 
50% PLA-PEtG 133 ± 10 0.17 ± 0.03 122 ± 8 0.12 ± 0.03 
100% PLA 138 ± 9 0.17 ± 0.04 109 ± 10 0.13 ± 0.04 
*The data recorded for unloaded particles were repeated for comparison. 
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Figure 29. Representative DLS diameter distributions for each letrozole-loaded PLA-PEtG blend. 
(a) volume distributions and (b) intensity distributions.  
Loaded particles prepared from 100% PEtG and 50% PLA-PEtG were also examined by 
TEM (Figure 30). The images show mostly spherical particles with diameters of 50–80 
nm. As mentioned above, the average particle diameter in the TEM images are smaller 
than those measured by DLS.  
 
Figure 30. TEM images of letrozole-loaded (a) 100% PEtG NPs and (b) 50% PLA-PEtG NPs. 
a b 
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3.5.2 Triggerable Release of Letrozole  
The novelty of the PEtG system, being the rapid burst release after triggering, posed a 
challenge of tracking released drug using conventional methods like dialysis. It was 
observed that the particles degraded so rapidly after application of the stimuli that the 
drug precipitated, leading to sedimentation within the dialysis membrane (Figure A-6a). 
On the other hand, the BnCO-PEtG controls showed no precipitation or sedimentation 
over the same time frame (Figure A-6b). Measurements of the dialysate were therefore 
not an accurate representation of released drug. To overcome this, 200 µL samples were 
taken of the contents within the dialysis membrane at incremental time points. These 200 
µL samples were passed through 0.22 µm syringe filters. The resulting filtered 
suspensions were then diluted with acetonitrile to dissolve the particles and remaining 
encapsulated drug. The absorbance was measured at 240 nm to quantify the amount of 
drug that had remained encapsulated. The study was conducted for NVOC-PLA-PEtG 
NPs. BnCO-PEtG particles were used as the non-responsive control and non-irradiated 
NVOC-PEtG (PLA-PEtG-nonirr.) particle samples were also measured as an additional 
control. In Figure 31, the release of letrozole from each PLA-PEtG particle system is 
shown. Figure 32 shows the release profiles for each of the control samples.   
 
Figure 31. Release profile of letrozole-loaded, UV-irradiated NVOC-PEtG particles. 
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Figure 32. Release profile of letrozole-loaded particle controls: BnCO-PEtG and negative 
controls. 
After irradiation with UV light, a significant burst release was observed with the 
irradiated NVOC-PEtG particles, which was not seen in the 100% PLA sample or the 
control samples. This can be attributed to successful and specific triggerable release using 
UV light as a stimulus in this study. For example, the 100% NVOC-PEtG particles 
released over 80% of the encapsulated letrozole over the first hour whereas the non-
irradiated control retained essentially all of the encapsulated drug for more than 100 h. 
The second important observation was the noticeable trend of increasing wt% PLA 
leading to a plateau in drug release at increased remaining drug percentages. This is 
consistent with previous DLS and Nile red studies. The only major exception to this 
general trend was several of the 100% NVOC-PEtG measurements which had higher 
retained drug, which could result from some particle destabilization and aggregation or 
simply the sample-to-sample variability on the measurements. The third, unfavorable 
observation was the relatively fast rate of release of letrozole from the control particles. 
Approximately 20 – 40% of letrozole was released from all control samples except non-
irradiated 100% PEtG over the period of five days. The release may arise from letrozole 
partitioning gradually into the aqueous environment and diffusing out through the 
dialysis membrane. The solubility of letrozole is 80 µg/mL in water. This value 
multiplied by 100 mL of dialysate equates to 8 mg that can be dissolved in the dialysate. 
Only 3 mg of letrozole was used in this study per sample so passive diffusion of the 
controls into the dialysate is plausible. 
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3.5.3 Triggerable Release of Celecoxib 
To test a different stimuli-responsive end-cap in this system, particles were synthesized 
using a reduction-sensitive end-cap containing a disulfide bond. The common small 
triggering molecule used in these systems is DTT. Complications arose when attempting 
to monitor the release of cargo from disulfide-PEtG particles using letrozole and 
celecoxib due to DTT having strong absorbance character in the 200−250 nm region. The 
absorbance of the stimulus gave inconsistent results in release studies by drowning out 
the signal of the drug molecule, even when accounted for when running a background of 
the same concentration of stimulus present. To overcome the erroneous data acquired 
from background stimulus in the sample, a different approach to measuring the release 
was needed. It was hypothesized that the quick release could be taken advantage of using 
centrifugation. After release, the precipitated drug could be removed by centrifugation to 
collect a pellet at incremental time points. The remaining particle suspension could be 
decanted off and the study continued, leaving released drug as a pellet that could be 
dissolved then the concentration quantitatively measured to determine the amount of 
released drug. This would avoid the presence of stimulus absorbance when measuring the 
UV absorbance. 
Celecoxib was chosen to show versatility in potential cargo encapsulation, as well as for 
its high loading efficiency and drug content. Particles were prepared as with previous 
studies, including each PLA-PEtG blend, pure PEtG, pure PLA particles. The samples 
were in 100 mM, pH 7.4 phosphate buffer and kept in a 37 °C oven for the duration. DTT 
was used as the stimulus with a concentration of 15 mmol introduced to both the 
disulfide-PEtG and BnCO-PEtG control samples. No DTT was added for separate 
disulfide-PEtG samples for a negative control. At specific time points, the samples were 
centrifuged and the pellet was collected. The pellet was distributed into thirds and 
dissolved in 1 mL acetonitrile. At the first time point, the disulfide-PEtG samples were 
instead dissolved into 1 mL d3-acetonitrile for NMR analysis. It was important to 
distinguish if the pellet contained significant amounts of intact PEtG which could signify 
presence of intact particles in the pellet. The samples were analyzed using UV-Vis 
spectroscopy to determine the concentration of celecoxib present in the pellet. The 
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release profiles for the DTT-treated particles are shown in Figure 33a. and the controls 
are shown in Figure 33b. 
 
Figure 33. Release profile of celecoxib-loaded PLA-PEtG-disulfide NPs and their controls. (a) 
celecoxib-loaded, 15 mmol DTT added PLA-PEtG-disulfide particles and (b) celecoxib-loaded 
particle controls: BnCO-PEtG and negative control. 
The same general trend seen in the DLS and Nile red studies was observed for the release 
of celecoxib. Pure PEtG particles exhibited the fastest release and with increasing PLA 
content, the release is slowed. There is no significant burst release seen in this study 
which is consistent with previous reduction-responsive particle studies. The controls 
appear to be roughly linear in their release profile with no significant burst release. The 
gradual, slow release of celecoxib in these samples is consistent across both the control 
samples and the disulfide-PEtG with no added DTT samples. The release from the 
controls can be attributed to slow, passive diffusion of the celecoxib out of the particles.   
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It is important to note that the centrifugation method is not a perfect analysis. For 
example, during centrifugation, not all of the precipitated drug goes into the pellet. There 
is visible drug still suspended in the decanted solution that is not being accounted for in 
the release. The small portion of drug left suspended in the sample may account for the 
pure PEtG sample not reaching 100% release. The presence of free drug was a noticeable 
problem with both the 100% PEtG sample and 10% PLA-PEtG sample. It is possible that 
the release in these two samples is much faster than what is shown. Secondly, there is an 
unavoidable small volume (~ 100 µL) of sample that remains in the centrifuge tube after 
decanting. This residual volume, although small, does contain particles encapsulated with 
celecoxib. It also is possible that some of the “release” depicted in the controls is actually 
celecoxib that was still encapsulated within intact particles in this residual small volume.  
The pellet content was also examined by NMR spectroscopy to determine qualitatively 
the presence of PEtG. Stimuli-responsive samples should show very little intact PEtG 
peaks and should compose mostly of celecoxib peaks and/or PLA peaks. If there exists 
significant PEtG, it is possible that either particles were present in the pellet or in the 
residual sample left after decanting. NMR spectra were taken for each sample at t = 4 h 
and t = 24 h post-DTT treatment. The aromatic peaks of celecoxib are used as an 
indicator of the presence of celecoxib. The backbone proton of PLA appears as a broad 
singlet at 5.1 ppm and the backbone proton of PEtG appears as another broad singlet at 
5.6 ppm. This can be examined for each sample in the celecoxib release study found in 
appendix Figures A-16–A-27. The 10% PLA-PEtG-disulfide sample is depicted in Figure 
34 for discussion. Coinciding with the concentration of celecoxib found by UV-vis 
spectroscopy, the NMR spectrum of 10% PLA-PEtG-disulfide shows the majority of the 
pellet to be celecoxib. There is very minimal intact PEtG present as can be concluded 
from the absence of the proton signal in the backbone of the intact polymer. There is a 
sharp singlet present at 5.7 ppm which is consistent with the hydrated version of the ethyl 
glyoxylate monomer. There is also presence of PLA in the pellet which is most likely due 
to the precipitated of PLA in the aqueous environment as the PEtG degrades, 
destabilizing the PLA portions of the particles. The 24 h spectrum is consistent with the 
UV data where a significant portion of celecoxib was not released at this time point. Each 
disulfide-PEtG sample showed similar NMR spectra results, the most important result 
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being the absence of intact PEtG. The BnCO-PEtG control samples as well as the 
disulfide-PEtG with no DTT stimulus controls do show some intact PEtG in their spectra.  
 
 
Figure 34. 1H NMR spectra of pellet collected from celecoxib release study of 10% PLA-PEtG-
disulfide sample after 4 and 24 h (CD3CN, 400 MHz). 
Overall, from the celecoxib release profiles, along with the NMR spectra, it can be 
concluded that celecoxib could be triggered to release from the PLA-PEtG-disulfide 
particles to a much higher extent than from control samples. Furthermore, increasing 
PLA content led to a slower release rate over a 24 h period. These data are consistent 
with the letrozole-loaded NVOC-PEtG studies, as well as, the DLS and Nile red studies. 
3.6 PLA-PEtG NP Cell Viability Studies 
It was important to determine how these particles behaved in vitro to ascertain 
effectiveness of PLA-PEtG NPs as potential DDSs. To study their behavior in cells, MTT 
(3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assays were conducted 
on MDA-MB-231, human breast cancer cells. This assay measures the metabolic 
activities of cells. In living and metabolically active cells, the MTT reagent is reduced to 
a compound that can be measured spectrophotometrically. Due to the high loading 
efficiency and drug content, celecoxib was chosen as the cargo molecule for these 
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studies. Cells were seeded on 96-well plates for each cell viability study. Free celecoxib, 
unloaded 100% NVOC-PEtG, unloaded 50% PLA-PEtG-NVOC, non-irradiated 
celecoxib-loaded 100% NVOC-PEtG and non-irradiated celecoxib-loaded 50% PLA-
PEtG-NVOC were each administered to a seeded, 96-well plate and allowed to incubate 
for 48 h to determine the cell viability for each of these controls. Untreated cells grown in 
the aforementioned media, as well as a media-only control were tested. Lastly, celecoxib-
loaded 100% NVOC-PEtG and celecoxib-loaded 50% PLA-PEtG-NVOC were 
administered to the cells. The cells were then irradiated with 30 minutes of 360 nm light 
using light emitting diode flashlights. 
It is hypothesized that the particles will enter the cell by the active transportation via 
endocytosis and exist in vesicles inside the cell where the release of cargo can occur. 
Unloaded 100% PEtG and 50% PLA-PEtG particles were studied to determine the 
toxicity of the materials themselves. Neither particles showed signs of cell toxicity even 
at 1 mg/mL, the highest concentration of particles evaluated (Figure 35). Free celecoxib 
had a half maximal inhibitory concentration (IC50) of 79 µM which is consistent with the 
literature value (Figure 36).87 For the celecoxib-loaded particles and celecoxib-loaded-
irradiated particles, the concentration was plotted as the log of celecoxib concentration to 
compare cell viability of free celecoxib with irradiated and non-irradiated cell plates. The 
concentration of celecoxib in the loaded particles was calculated based on the loaded 
wt% of celecoxib within the particles multiplied by the concentration of particles 
administered. These plots are shown in Figure 36 and Figure 37. From the data, several 
conclusions can be made. First, the celecoxib-loaded particles were much less toxic than 
the free drug. Significant cell death was only seen at the highest concentration of particles 
(~ 600 μM of drug). This suggests that the free drug was not released fully within the 
cells or was released over a longer time frame, leading to lower toxicity. In addition, the 
UV irradiated particles showed no significant difference in toxicity relative to the non-
irradiated particles. It would be expected that irradiated particles would release their 
celecoxib contents and induce cell death in this manner, but this was not seen. It could be 
possible that the celecoxib was precipitating out of solution once released, as seen in the 
release studies. In addition, it is known known whether the particles were taken up by 
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cells. This will require further investigation and other stimuli will need to be studied. 
However, it is still important to conclude that PEtG NPs showed no toxicity to MDA-
MB-231 cells and they could decrease the celecoxib toxicity to this cell line. 
 
Figure 35. MTT assays of unloaded 100% NVOC-PEtG and unloaded 50% PLA-PEtG-NVOC 
NPs in MDA-MB-231 cells. Error bars represent the standard deviations on the measurements. 
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Figure 36. MTT assay cell viability studies of free celecoxib, 100% NVOC-PEtG-loaded and 
100% NVOC-PEtG-loaded irradiated with 30 minutes of UVA light in MDA-MB-231 cells. 
Error bars represent the standard deviations on the measurements. 
 
 
Figure 37. MTT assay cell viability studies of free celecoxib, 50% PLA-PEtG-NVOC-loaded and 
50% PLA-PEtG-NVOC-loaded irradiated with 30 minutes of UVA light in MDA-MB-231 cells. 
Error bars represent the standard deviations on the measurements. 
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4 Conclusions & Future Work 
The results of this work led to several significant findings relevant to the use of PEtG in 
DDSs. First, it was shown that PEtG can be used as hydrophobic homopolymer to 
synthesize polymeric NPs using an O/W emulsion technique. 100% PEtG NPs are stable 
in solution and can be synthesized with ~100 nm diameters, which is in the optimal range 
for intravenous injection. These particles were demonstrated to be stimuli-responsive 
when manufactured with a stimuli-responsive end-capped PEtG. These stimuli-
responsive particles could be loaded with a hydrophobic cargo and triggered to release 
that cargo upon introduction of relatively small concentrations of stimulus.  
In addition, while pure PEtG NPs rapidly release a large fraction of their cargo in 
response to stimuli, it was possible to tune the extent of this burst release using blends 
with PLA. By changing the wt% PLA, it was found that the release rates of cargo 
molecules can be tuned. Increasing PLA character led to a slower release of cargo. The 
morphology and diameter of blended particles showed no significant difference to 100% 
PEtG particles. This was confirmed by DLS and TEM. 
Two stimuli-responsive end-capped PEtG NPs were studied in this work, UV light 
sensitive and reduction sensitive. These two stimuli-responsive particles had interesting 
differences in their release profiles. NVOC-PEtG particles showed a very rapid, burst 
release within the first hour post-UV irradiation. This was followed by a plateau region 
correlating to the amount of PLA present in the particles. This gave a two-part release: a 
quick burst release of drug at the beginning due to rapid degradation of PEtG followed by 
a slower release of drug from the remaining PLA domains. Disulfide-PEtG particles 
showed less initial burst release, but still showed slower release with increasing PLA 
content. These trends were seen for DLS studies, Nile red studies and hydrophobic drug 
studies.  
Finally, PLA-PEtG NPs showed no toxicity to MDA-MB-231 cells, even at the highest 
concentration of particles evaluated (1 mg/mL). When these particles were loaded with 
celecoxib, no toxicity was seen until a concentration of 600 µM. This is well above the 
IC50 of celecoxib which is reported to be around 79 µM in MDA-MB-231 cells. 
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Unfortunately, it was found that celecoxib-loaded NVOC-PEtG particles administered to 
this cell line did not show a decrease of cell viability when irradiated with 30 minutes of 
UV light. It is not known if the nanoparticles were taken up by cells. This would require 
further studies to investigate this using labeled particles. It is also possible that the 
released celecoxib could be precipitating out of solution, therefore unavailable to the 
cells. 
To extend this work, several areas could be further investigated. First, research towards 
alternative surfactants could produce PEtG particles that are less susceptible to 
aggregation upon drying. This would allow for ease in drying and dispersing the particles 
back into solution, increasing their shelf-life. Second, it would also be interesting to test a 
library of stimuli-responsive particles by exchanging the end-cap on PEtG. This would 
increase the versatility of PEtG NPs and possibly increase their potential applications. 
This work tested UV and reduction-responsive particles. Particles responsive to pH or 
temperature might lead to interesting applications. Lastly, further investigation into 
cellular uptake is essential. Why UV-responsive, celecoxib-loaded particles irradiated 
with UV light did not lead to a significant drop in cell viability remains unknown. 
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Appendix 
 
Figure A-1. Letrozole calibration curve in acetonitrile ( = 240 nm,  = 30,600 L/cm·cm). 
 
 
Figure A-2. Celecoxib calibration curve in acetonitrile ( = 253 nm,  = 16,400 L/cm·cm). 
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Figure A-3. TEM images of (a) pure BnCO-PEtG NPs, (b) 10 wt% PLA, (c) 30 wt% PLA, and 
(d) 50 wt% PLA.  
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Figure A-4. Determination of particle diameters and disparities by DLS for PLA-PEtG-BnCO 
blends. (a) intensity distribution and (b) volume distribution. 
 
Figure A-5. Determination of particle diameter and dispersity by DLS for PLA-PEtG-disulfide 
blends. (a) intensity distribution and (b) volume distribution. 
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Table A-1. Z-avg. and polydispersity indices for the PLA-PEtG-BnCO & disulfide blends. 
Blend 
Z-avg. (nm) 
BnCO 
PDI 
Z-avg. (nm) 
disulfide 
PDI 
0% PLA 128 ± 15 0.11 ± 0.05 129 ± 11 0.17 ± 0.07 
10% PLA 144 ± 16 0.17 ± 0.06 130 ± 6 0.11 ± 0.03 
30% PLA 127 ± 11 0.11 ± 0.02 122 ± 6 0.09 ± 0.01 
50% PLA 131 ± 4 0.14 ± 0.02 124 ± 12 0.12 ± 0.03 
 
 
Figure A-6. UV-light irradiated letrozole-containing NPs based on (a) NVOC-PEtG NPs 
(containing letrozole precipitates) and (b) BnCO-PEtG control, in a dialysis membrane bags.  
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Figure A-7. Celecoxib precipitates formed from celecoxib-containing NPs based on disulfide-
PEtG upon the addition of DTT at (a) 0 and (b) 4 h. 
 
 
Figure A-8. Celecoxib precipitates formed from celecoxib-containing NPs based on PLA-PEtG-
disulfide blends upon the addition of DTT after 4 h. (a) 100% PEtG, (b) 10% PLA-PEtG, (c) 30% 
PLA-PEtG, and (d) 50% PLA-PEtG.  
a b 
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Figure A-9. Celecoxib precipitates formed from celecoxib-containing NPs based on PLA-PEtG-
disulfide blends upon the addition of DTT after 24 h. (a) 100% PEtG, (b) 10% PLA-PEtG, (c) 
30% PLA-PEtG, and (d) 50% PLA-PEtG. 
 
 
Figure A-10. Celecoxib precipitates formed from celecoxib-containing NPs based on BnCO-
PEtG control blends upon the addition of DTT after 4 h. (a) 100% PEtG, (b) 10% PLA-PEtG, (c) 
30% PLA-PEtG, and (d) 50% PLA-PEtG. 
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Figure A-11. Celecoxib-containing NPs based on BnCO-PEtG control blends upon the addition 
of DTT after 24 h. (a) 100% PEtG, (b) 10% PLA-PEtG, (c) 30% PLA-PEtG, and (d) 50% PLA-
PEtG. 
 
 
Figure A-12. Celecoxib-containing NPs based on PLA-PEtG-disulfide blends after 4 h. (a) 100% 
PEtG, (b) 10% PLA-PEtG, (c) 30% PLA-PEtG, and (d) 50% PLA-PEtG. 
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Figure A-13. Celecoxib-containing NPs based on PLA-PEtG-disulfide blends after 24 h. (a) 
100% PEtG, (b) 10% PLA-PEtG, (c) 30% PLA-PEtG, and (d) 50% PLA-PEtG. 
 
 
Figure A-14. 1H NMR spectrum of celecoxib (CD3CN, 400 MHz). 
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Figure A-15. 1H NMR spectrum of poly(D,L-lactic acid) (CD3CN, 400 MHz). 
 
 
Figure A-16. 1H NMR spectrum of disulfide-PEtG recorded during the celecoxib release studies 
(CD3CN, 400 MHz). 
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Figure A-17. 1H NMR spectrum of pellet collected from celecoxib release study of 100% 
disulfide-PEtG sample after 4 and 24 h (CD3CN, 400 MHz). 
 
Figure A-18. 1H NMR spectrum of pellet collected from celecoxib release study of 100% 
disulfide-PEtG no DTT control sample after 4 and 24 h (CD3CN, 400 MHz). 
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Figure A-19. 1H NMR spectrum of pellet collected from celecoxib release study of 100% 
BnCO-PEtG control sample after 4 and 24 h (CD3CN, 400 MHz). 
 
Figure A-20. 1H NMR spectrum of pellet collected from celecoxib release study of 10% PLA-
PEtG-disulfide sample after 4 and 24 h (CD3CN, 400 MHz). 
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Figure A-21. 1H NMR spectrum of pellet collected from celecoxib release study of 10% PLA-
PEtG-disulfide no DTT control sample after 4 and 24 h (CD3CN, 400 MHz). 
 
Figure A-22. 1H NMR spectrum of pellet collected from celecoxib release study of 10% PLA-
PEtG-BnCO control sample after 4 and 24 h (CD3CN, 400 MHz). 
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Figure A-23. 1H NMR spectrum of pellet collected from celecoxib release study of 30% PLA-
PEtG-disulfide sample after 4 and 24 h (CD3CN, 400 MHz). 
 
Figure A-24. 1H NMR spectrum of pellet collected from celecoxib release study of 30% PLA-
PEtG-disulfide no DTT control sample after 4 and 24 h (CD3CN, 400 MHz). 
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Figure A-25. 1H NMR spectrum of pellet collected from celecoxib release study of 30% PLA-
PEtG-BnCO control sample after 4 and 24 h (CD3CN, 400 MHz). 
 
Figure A-26. 1H NMR spectrum of pellet collected from celecoxib release study of 50% PLA-
PEtG-disulfide sample after 4 and 24 h (CD3CN, 400 MHz). 
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Figure A-27. 1H NMR spectrum of pellet collected from celecoxib release study of 50% PLA-
PEtG-disulfide no DTT control sample after 4 and 24 h (CD3CN, 400 MHz). 
 
Figure A-28. 1H NMR spectrum of pellet collected from celecoxib release study of 100% PLA 
sample after 4 and 24 h (CD3CN, 400 MHz). 
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Figure A-29. 1H NMR spectrum of NVOC-PEtG (CDCl3, 400 MHz).  
 
 
Figure A-30. 1H NMR spectrum of BnCO-PEtG (CDCl3, 400 MHz). 
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Figure A-31. 1H NMR spectrum of disulfide-PEtG (CD3CN, 400 MHz). 
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